In a study of patients receiving EGFR TKI (as any line of treatment) for advanced lung adenocarcinoma harboring (either common or uncommon) EGFR mutation by Chiu et al. [13], female sex, elderly (age > 70 years), and common EGFR mutation were independent factors suggesting better PFS. Here, EGFR is linked to lung adenocarcinoma.